Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging

The inclusion of LiverMultiScan, either as an adjunct to or replacement of transient elastography (TE) in the diagnostic pathway of NAFLD, leads to cost savings for the NHS by reducing the number of liver biopsies required. When used in place of TE and liver biopsy, LiverMultiScan remains cost-effective up to a price of £672.